Effects of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma with different proportions on glucose and lipid metabolism in rats with non-alcoholic fatty liver disease

Qiang ZHANG; Kaili LIU; Jun JIN; Li ZHANG; Jun RUAN; Haonan SHANG; Junming CHEN; Tiegang XIAO; Bing WANG

doi:10.16305/j.1007-1334.2021.2011155

您当前的位置：

首页 >

文章列表页 >

Effects of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma with different proportions on glucose and lipid metabolism in rats with non-alcoholic fatty liver disease

更新时间：2022-08-03

- Effects of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma with different proportions on glucose and lipid metabolism in rats with non-alcoholic fatty liver disease
- Shanghai Journal of Traditional Chinese Medicine Vol. 55, Issue 8, Pages: 80-87(2021)
- 作者机构：
  
  1.上海交通大学附属第六人民医院中医科（上海　200233）
  2.上海交通大学附属第六人民医院老年病科（上海　200233）
  3.上海健康医学院附属周浦医院中医科（上海　201318）
  4.上海中医药大学附属上海市中西医结合医院消化科（上海　200082）
- 作者简介：
- 基金信息：
- DOI：10.16305/j.1007-1334.2021.2011155
  CLC：
扫描看全文
Qiang ZHANG, Kaili LIU, Jun JIN, et al. Effects of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma with different proportions on glucose and lipid metabolism in rats with non-alcoholic fatty liver disease. [J]. Shanghai Journal of Traditional Chinese Medicine 55(8):80-87(2021)
DOI：

Qiang ZHANG, Kaili LIU, Jun JIN, et al. Effects of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma with different proportions on glucose and lipid metabolism in rats with non-alcoholic fatty liver disease. [J]. Shanghai Journal of Traditional Chinese Medicine 55(8):80-87(2021) DOI： 10.16305/j.1007-1334.2021.2011155.

摘要

目的,2,探索不同配伍比例柴胡人参药对对非酒精性脂肪性肝病（NAFLD）大鼠糖脂代谢的影响。,方法,2,将48只Wistar大鼠随机分为正常组（C组）8只和造模组40只。C组给予普通饲料及0.9%NaCl溶液灌胃，造模组给予高脂高糖饲料及0.9%NaCl溶液灌胃，造模成功后将造模组大鼠随机分成模型组（M组）、柴胡人参1∶1组（CR 1∶1组）、柴胡人参1∶2.5组（CR 1∶2.5组）、柴胡人参2.5∶1组（CR 2.5∶1组）、奥贝胆酸组（OB组），每组8只。各用药组给予高脂高糖饲料及相应药物灌胃。各组干预结束后称量大鼠体质量、肝湿重，观察病理染色，检测肝功能、血脂、空腹血糖（FBG）、胰岛素敏感指数（ISI）和胰岛素抵抗指数（HOMA-IR）。,结果,2,与正常组比较，M组大鼠丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、总胆固醇（TC）、三酰甘油（TG）、FBG、胰岛素含量（FINS）、胰岛素抵抗指数（HOMA-IR）水平升高，胰岛素敏感指数（ISI）水平下降，肝脏脂肪变性及炎症程度加重。与M组比较，各用药组的糖代谢、脂代谢有一定程度的改善。具体而言，各用药组之间比较，CR 2.5∶1组的体质量、肝湿重，以及TC、ALT、AST、FBG、FINS、HOMA-IR、脂肪变性及炎症评分下降较其余两组显著，ISI水平升高也最显著，故柴胡人参配伍2.5∶1时的药效作用最佳；与OB组比较，CR 2.5∶1组体质量水平下降更为显著，而肝湿重、TC、AST、FBG、ISI及炎症评分的改善不如OB组显著。,结论,2,柴胡人参药对可以改善NAFLD大鼠的糖脂代谢，其最佳配伍比例为柴胡与人参2.5∶1。

Abstract

Objective,2,To explore the effects of different compatibility ratios of drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma on glucose and lipid metabolism in non-alcoholic fatty liver disease (NAFLD) rats.,Methods,2,Forty-eight Wistar rats were randomly divided into a normal group (group C) with 8 rats and a modeling group with 40 rats. The rats in Group C was given normal feed and 0.9% NaCl solution by gavage, and the rats in the modeling group was given high-fat and high-sugar feed and 0.9% NaCl solution by gavage. After the model was successfully built, the model rats were randomly divided into model group (group M), drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma 1∶1 group (CR 1∶1 group), drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma 1∶2.5 group (CR 1∶2.5 group), drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma 2.5∶1 group (CR 2.5∶1 group) and obeticholic acid group (OB group), 8 rats in each group. Each medication group was given high-fat and high-sugar feed and corresponding drugs by gavage. After the intervention, the body weight and liver wet weight of the rats were weighed, the pathological staining was observed, and the liver function, blood lipid, fasting blood glucose (FBG), insulin sensitivity index (ISI) and insulin resistance index (HOMA-IR) were measured.,Results,2,Compared with the group C, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triacylglycerol (TG), FBG, insulin content (FINS) and HOMA-IR increased, while insulin sensitivity index (ISI) level decreased, and liver steatosis and inflammation aggravated in group M of rats. Compared with group M, the glucose metabolism and lipid metabolism of each medication group were improved to a certain extent. Comparison between medication groups, the body weight, liver wet weight, TC, ALT, AST, FBG, FINS, HOMA-IR, and steatosis and inflammation scores of the CR 2.5∶1 group decreased significantly compared with the other two groups; the increase in ISI level is also the most significant; the drug effect is the best when the proportion of Bupleuri Radix to Ginseng Radix et Rhizoma is 2.5∶1. Compared with the OB group, the body mass level of CR 2.5∶1 group decreased more significantly, while the liver wet weight, TC, AST, and the improvement of FBG, ISI and inflammation score were not as significant as those of OB group.,Conclusion,2,The drug pair of Bupleuri Radix and Ginseng Radix et Rhizoma can improve the glucose and lipid metabolism of NAFLD rats, and the best compatibility ratio of Bupleuri Radix to Ginseng Radix et Rhizoma is 2.5∶1.

关键词

柴胡人参模型大鼠非酒精性脂肪性肝病糖代谢脂代谢中药研究

Keywords

Bupleuri RadixGinseng Radix et Rhizomamodel ratsnon-alcoholic fatty liver diseaseglucose metabolismlipid metabolismresearch on traditional Chinese medicine

references

RINELLA M E. Nonalcoholic fatty liver disease: a systematic review[J]. JAMA, 2015, 313(22): 2263-2273.

ZHOU F, ZHOU J, WANG W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133.

CHALASANI N, YOUNOSSI Z, LAVINE J E, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6): 2005-2023.

IBRAHIM S H, HIRSOVA P, GORES G J. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation[J]. Gut, 2018, 67(5): 963-972.

ESLAM M, SANYAL A J, GEORGE J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.

KNODELL R G, ISHAK K G, BLACK W C, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[J]. Hepatology, 1981, 1(5): 431-435.

王泰龄，刘霞，周元平. 慢性肝炎炎症活动度及纤维化程度计分方案[J]. 中华肝脏病杂志，1998, 6(4): 195.

FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.

GARINIS G A, FRUCI B, MAZZA A, et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study[J]. Int J Obes (Lond), 2010, 34(8): 1255-1264.

TORRES D M, JONES F J, SHAW J C, et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open-label trial[J]. Hepatology, 2011, 54(5): 1631-1639.

RAKOSKI M O, SINGAL A G, ROGERS M A, et al. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2010, 32(10): 1211-1221.

KUCHAY M S, KRISHAN S, MISHRA S K, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)[J]. Diabetes Care, 2018, 41(8): 1801-1808.

YOUNOSSI Z M, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196.

SANYAL A J, CHALASANI N, KOWDLEY K V, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 362(18): 1675-1685.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J]. Diabetologia, 2016, 59 (6): 1121-1140.

WEI X, WANG C, HAO S, et al. The therapeutic effect of berberine in the treatment of nonalcoholic fatty liver disease: a meta-analysis[J/OL]. Evid Based Complement Alternat Med, 2016[2020-11-05].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947506/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947506/.

ZEIN C O, YERIAN L M, GOGATE P, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial[J]. Hepatology, 2011, 54(5): 1610-1619.

RAHMANI S, ASGARY S, ASKARI G, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial[J]. Phytother Res, 2016, 30(9): 1540-1548.

DANESHI-MASKOONI M, KESHAVARZ S A, QORBANI M, et al. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial[J]. BMC Complement Altern Med, 2019, 19(1): 59.

YANG F, DONG X, YIN X, et al. Radix Bupleuri: a review of traditional uses, botany, phytochemistry, pharmacology, and toxicology[J/OL]. Biomed Res Int, 2017[2020-11-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448051/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448051/.

WANG Y X, LIU Q Y, ZHANG M, et al. Polysaccharides from bupleurum induce immune reversal in late sepsis[J]. Shock, 2018, 49(4): 451-459.

JIANG H, YANG L, HOU A, et al. Botany, traditional uses, phytochemistry, analytical methods, processing, pharmacology and pharmacokinetics of Bupleuri Radix: A systematic review[J]. Biomed Pharmacother, 2020(131): 110679.

黎阳，张铁军，刘素香，等. 人参化学成分和药理研究进展[J]. 中草药，2009, 40(1): 164-166.

ZHOU P, XIE W, HE S, et al. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis[J]. Cells, 2019, 8(3): 204.

SU G Y, LI Z Y, WANG R, et al. Signaling pathways involved in p38-ERK and inflammatory factors mediated the anti-fibrosis effect of AD-2 on thioacetamide-induced liver injury in mice[J]. Food Funct, 2019, 10(7): 3992-4000.

LU K H, WENG C Y, CHEN W C, et al. Ginseng essence, a medicinal and edible herbal formulation, ameliorates carbon tetrachloride-induced oxidative stress and liver injury in rats[J]. J Ginseng Res, 2017, 41(3): 316-325.

阮君，肖铁刚，王兵. 柴胡皂苷D对非酒精性脂肪性肝炎大鼠糖脂代谢紊乱的影响[J]. 中西医结合肝病杂志，2019,29(5): 399-401.

阮君，肖铁刚，陈珺明，等. 人参总皂苷调节非酒精性脂肪肝病大鼠糖脂代谢紊乱机制研究[J]. 中华中医药学刊，2020, 38(8): 101-106.

何道同，陈珺明，宋海燕，等. 柴胡人参药对对非酒精性脂肪性肝病大鼠胰岛素抵抗和瘦素的影响[J]. 中西医结合肝病杂志，2013, 23(2): 98-100.

肖铁刚，何道同，陈珺明，等. 柴胡人参药对对非酒精性脂肪性肝病大鼠法尼醇X受体和固醇调节元件结合蛋白-1c表达的影响[J]. 中西医结合肝病杂志，2014, 24(4): 234-238.

Views

302

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical and biochemical characteristics of polycystic ovary syndrome in obese women of phlegm constitution

Key problems in terminology standardization of Ginseng Radix et Rhizoma varieties

Research progress on alkaloid active ingredients in Nelumbinis Folium against non‑alcoholic fatty liver disease

Study on clinical characteristics and TCM constitution distribution pattern of lean MAFLD in the elderly in Shanghai communities

Analysis of fundus image features in NAFLD patients with internal accumulation of damp⁃heat syndrome and liver depression and spleen deficiency syndrome

Related Author

No data

Related Institution

Institute of International Standardization of Traditional Chinese Medicine， Shanghai University of Traditional Chinese Medicine

Shanghai Academy of International Standardization for Traditional Chinese Medicine

Department of Clinical Standardization， Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Interdisciplinary Integrative Medicine Research， Shanghai University of Traditional Chinese Medicine

Longhua Clinical Medical College， Shanghai University of Traditional Chinese Medicine

⁰